1～3 月，生物药品制造业累计实现主营业务收入604.06 亿元，同比增长9.45%，增速较上年同期下降4.51 个百分点；实现利润总额76.40 亿元，同比增长19.99%。

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面对医药行业进行了分析评论。

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面对医药行业进行了分析评论。

2015 年1～2 月，受到春节等因素影响，医药行业产销增速有所下降。其中，中成药产量同比下降10.14%，化学原料药产量同比增长4.7%，较上年同期下降23.5 个百分点。

1～5月，生物药品制造业累计实现主营业务收入1059.93 亿元，同比增长 8.32%，增速较 1～ 4月下降 0.93 个百分点。

5月，医药品市场需求偏弱，医药行业产销增速有所回落。其中，中成药产量环比下降 10.13%，中西药品单月零售总额环比下降 2.7%，医药制造业工业品出厂价格指数环比下降 0.22 点。

6 月，医药品市场需求回升，医药行业产销增速有所上升。其中，中成药产量环比增长 11.94%，化学原料药产量环比增长 4.78%，中西药品单月零售总额环比增长 10.81%。

1～ 6 月，生物药品制造业累计实现主营业务收入1343.99 亿元，同比增长 8.38%，增速较 1～ 5 月上升 0.06 个百分点；实现利润总额 176.32 亿元，同比增长 18.77%，增速较 1～ 5 月上升 3.05个百分点； 行业资产负债率较 1～ 5 月下降 0.19 个百分点，为 34.01%。

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面对医药行业进行了分析评论。

1～4 月，生物药品制造业累计实现主营业务收入826.91 亿元，同比增长9.26%，增速较1～3 月下降0.19 个百分点；实现利润总额105.28 亿元，同比增长17.48%，增速较1～3 月小幅下降2.51 个百分点。

4 月，医药行业产销增速有所回升。其中，化学原料药产量环比增长7.55%，中西药品单月零售总额环比增长4%。在国家发改委放开药品价格管制的预期下，医药品价格增长逐步趋稳。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

1～2 月，生物药品制造业累计实现主营业务收入362.31 亿元，同比增长11.02%，增速较上年同期下降3.63 个百分点。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

3 月，医药行业产销增速有所下降。其中，化学原料药产量同比下降6.83%，而上年同期为同比增长4.50%；中西药品零售总额同比增长12.7%，较上年同期下降0.3 个百分点。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

Bone and mineral disorders are usually caused by abnormalities in minerals such as calcium, phosphorus, vitamin D, and in bone structure or bone mass. Osteoporosis, Paget's disease, and osteogenesis imperfecta are the most common bone diseases. Other diseases, such as arthritis and cancer and their respective treatments, also have adverse effects on bone. Bone and mineral diagnostic tests are used for the diagnosis and assessment of changes in response to bone disorder therapy. These tests are performed using various technologies such as the enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and radioimmunoassay (RIA) techniques.

Deodorants fall under the broad category of cosmetics. Their primary use is to prevent body odor that results from perspiration.

Syphilis is a type of sexually transmitted infectious disease caused by the bacteria Treponema pallidum subspecies pallidum. The infection spreads mainly through sexual contact. Congenital syphilis, however, affects infants by transmission of the infection from the infected mother to the fetus. Rate of syphilis infection is high among men and particularly in those men who have sex with men. In 2014, worldwide, around 36 million people were infected by syphilis. The global burden of syphilis is gradually increasing. Unprotected sex and sexual intercourse with multiple partners infected by syphilis are the key factors that contribute to spread of infection. However, early diagnosis of the infection enables quick recovery from the disease. Testing methods employed for syphilis detection include: enzyme immunoassay (EIA) test, venereal disease research laboratory (VDRL) test, rapid plasma reagin (RPR) test, and point of care (POC) test kits.

A PICC is a thin, soft, flexible tube used to inject fluids or medication directly into a vein and or to draw blood samples for testing. These devices are inserted in the arm into either the cephalic vein, or basilic vein, or brachial vein (commonly known as peripheral veins). The catheter is threaded through larger veins toward the heart until the tip of the tube rests in the distal superior vena cava or cavoatrial junction. The device has two openings known as lumens used to deliver medication.

According to the FDA, the orphan drug designation program provides orphan designation to drugs and biologics that are used for the safe and effective treatment, diagnosis, or prevention of rare diseases/disorders that affect less than 200,000 people in the US or that affect above 200,000 people but are not estimated to recover the costs of developing and marketing a treatment drug. Also, orphan drugs are developed by the pharmaceutical industry to serve the public health need. They are granted orphan drug status by the regulatory agencies to accelerate the approval process.